Physician profile
Michael J Everson
NPI 1356320287
$19,083.90
in general payments reported to CMS, 2019-2025
30 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $308 · 2021: $43.96 · 2022: $97.02 · 2023: $184 · 2024: $113 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17,216.97 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $445.25 | 2019-2025 | Rexulti |
| Allergan, INC. | $176.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $134.01 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $114.70 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.66 | 2022-2025 | Caplyta |
| Neos Therapeutics, Lp | $87.16 | 2019 | |
| Avanir Pharmaceuticals, INC. | $71.03 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $70.35 | 2020-2025 | |
| Tris Pharma INC | $68.45 | 2019-2023 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $63.46 | 2019-2023 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $54.94 | 2019-2023 | Austedo |
| Shire North American Group INC | $50.76 | 2019 | |
| Corium, LLC | $43.34 | 2024 | Azstarys |
| Abbvie INC. | $42.29 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $39.71 | 2024-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $35.44 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $33.88 | 2019-2023 | Jornay Pm |
| Alkermes, INC. | $28.05 | 2024 | Aristada, Lybalvi |
| Merck Sharp & Dohme LLC | $27.27 | 2020-2023 | Belsomra |
| Bausch Health US, LLC | $25.00 | 2025 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $22.06 | 2025 | Cobenfy |
| Alfasigma USA, INC. | $20.49 | 2020 | |
| Almatica Pharma LLC | $20.15 | 2025 | Loreev Xr |
| Acadia Pharmaceuticals INC | $15.84 | 2023 | Nuplazid |
| Eisai INC. | $15.83 | 2020 | |
| Amgen INC. | $15.82 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.56 | 2020 | |
| Harmony Biosciences LLC | $11.38 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Everson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.